INVESTMENT WATCH- GSK inaugurates new EGP 20 mn line: GlaxoSmithKline (GSK) Consumer Healthcare inaugurated a EGP 20 mn production line yesterday, according to an Investment Ministry statement (pdf). The company will now have 11 production lines at its Giza facility, allowing it to produce 90 million boxes of the pain med and anti-inflammatory Voltaren Emulgel.

GSK plans to invest EGP 100 mn this year: The UK-based company will invest a total of EGP 100 mn in Egypt this year, the ministry statement noted. This will bring its total investments in the country to EGP 1.1 bn. GSK will be investing in developing more production lines and ensuring its brands’ availability, North Africa General Manager Nabil Besri said (pdf).

More British business expected to come: UK-based health companies are planning to increase their investments under an “Egyptian-British plan” for the sector, British Ambassador Sir Geoffrey Adams said. “Britain has an ambitious plan for health care in Egypt,” Adams added without elaborating further.